Pharmaceutical Information For You !: GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer

Monday, February 1, 2010

GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer

- Company progresses commitments to increase transparency

Advertisement:

http://digg.com/u1M1Q7

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)